Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities-Reference-Cited by-同舟云学术

Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities

Published:2020-11-30 Issue:6 Volume:42 Page:697-699
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Pitt Bertram¹,Byrd James Brian¹

Affiliation:

1. University of Michigan School of Medicine, Department of Medicine, Division of Cardiovascular Medicine, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/42/6/697/36241201/ehaa765.pdf

Reference14 articles.

1. The evolution of aldosterone antagonists;Garthwaite;Mol Cell Endocrinol,2004

2. Presidental address: part I painting background; part II primary aldosteronism, a new clinical syndrome;Conn;J Lab Clin Med,1955

3. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial;Williams;Lancet,2015

4. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression;Staessen;J Endocrinol,1981

5. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin–angiotensin–aldosterone system;Weber;Circulation,1991

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mineralocorticoid receptor promotes cardiac macrophage inflammaging;Basic Research in Cardiology;2024-02-08

2. Sodium–glucose co-transporter 2 inhibition: the saga continues;European Heart Journal;2022-11-01

3. The far-reaching beneficial effects of sodium–glucose co-transporter 2 inhibitors in heart failure;European Heart Journal;2022-08-14

4. New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease;European Heart Journal;2021-02-07